169 related articles for article (PubMed ID: 25367854)
21. Dramatic Response to Catumaxomab Treatment for Malign Ascites Related to Renal Cell Carcinoma With Sarcomotoid Differentiation.
Pilanc KN; Ordu Ç; Akpnar H; Balc C; Başsülü N; Köksal Üİ; Elbüken F; Okutur K; Bülbül G; Sağlam S; Demir G
Am J Ther; 2016; 23(4):e1078-81. PubMed ID: 24732906
[TBL] [Abstract][Full Text] [Related]
22. Immunomonitoring results of a phase II/III study of malignant ascites patients treated with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3).
Jäger M; Schoberth A; Ruf P; Hess J; Hennig M; Schmalfeldt B; Wimberger P; Ströhlein M; Theissen B; Heiss MM; Lindhofer H
Cancer Res; 2012 Jan; 72(1):24-32. PubMed ID: 22044753
[TBL] [Abstract][Full Text] [Related]
23. Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy.
Seimetz D; Lindhofer H; Bokemeyer C
Cancer Treat Rev; 2010 Oct; 36(6):458-67. PubMed ID: 20347527
[TBL] [Abstract][Full Text] [Related]
24. Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer.
Knödler M; Körfer J; Kunzmann V; Trojan J; Daum S; Schenk M; Kullmann F; Schroll S; Behringer D; Stahl M; Al-Batran SE; Hacker U; Ibach S; Lindhofer H; Lordick F
Br J Cancer; 2018 Aug; 119(3):296-302. PubMed ID: 29988111
[TBL] [Abstract][Full Text] [Related]
25. Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study.
Sebastian M; Passlick B; Friccius-Quecke H; Jäger M; Lindhofer H; Kanniess F; Wiewrodt R; Thiel E; Buhl R; Schmittel A
Cancer Immunol Immunother; 2007 Oct; 56(10):1637-44. PubMed ID: 17410361
[TBL] [Abstract][Full Text] [Related]
26. Intraperitoneal catumaxomab therapy in a cirrhotic patient with malignant ascites due to urethelial carcinoma: a case report.
Krawczyk M; Zimmermann S; Vidacek D; Lammert F
Onkologie; 2012; 35(10):592-4. PubMed ID: 23038231
[TBL] [Abstract][Full Text] [Related]
27. Catumaxomab: clinical development and future directions.
Linke R; Klein A; Seimetz D
MAbs; 2010; 2(2):129-36. PubMed ID: 20190561
[TBL] [Abstract][Full Text] [Related]
28. Intra- and postoperative catumaxomab in patients with epithelial ovarian cancer: safety and two-year efficacy results from a multicentre, single-arm, phase II study.
Sehouli J; Reinthaller A; Marth C; Reimer D; Reimer T; Stummvoll W; Angleitner-Boubenizek L; Brandt B; Chekerov R
Br J Cancer; 2014 Oct; 111(8):1519-25. PubMed ID: 25225907
[TBL] [Abstract][Full Text] [Related]
29. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study.
Burges A; Wimberger P; Kümper C; Gorbounova V; Sommer H; Schmalfeldt B; Pfisterer J; Lichinitser M; Makhson A; Moiseyenko V; Lahr A; Schulze E; Jäger M; Ströhlein MA; Heiss MM; Gottwald T; Lindhofer H; Kimmig R
Clin Cancer Res; 2007 Jul; 13(13):3899-905. PubMed ID: 17606723
[TBL] [Abstract][Full Text] [Related]
30. Extraperitoneal response to intraperitoneal immunotherapy with catumaxomab in a patient with cutaneous lymphangiosis carcinomatosa from ovarian cancer: a case report and review of the literature.
Woopen H; Pietzner K; Darb-Esfahani S; Oskay-Oezcelik G; Sehouli J
Med Oncol; 2012 Dec; 29(5):3416-20. PubMed ID: 22744709
[TBL] [Abstract][Full Text] [Related]
31. Systemic effect of catumaxomab in a patient with metastasized colorectal cancer: a case report.
Bezan A; Hohla F; Meissnitzer T; Greil R
BMC Cancer; 2013 Dec; 13():618. PubMed ID: 24380380
[TBL] [Abstract][Full Text] [Related]
32. A phase II study of catumaxomab administered intra- and postoperatively as part of a multimodal approach in primarily resectable gastric cancer.
Bokemeyer C; Stein A; Ridwelski K; Atanackovic D; Arnold D; Wöll E; Ulrich A; Fischer R; Krüger C; Schuhmacher C
Gastric Cancer; 2015 Oct; 18(4):833-42. PubMed ID: 25214034
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients.
Ruf P; Kluge M; Jäger M; Burges A; Volovat C; Heiss MM; Hess J; Wimberger P; Brandt B; Lindhofer H
Br J Clin Pharmacol; 2010 Jun; 69(6):617-25. PubMed ID: 20565453
[TBL] [Abstract][Full Text] [Related]
34. The evolving role of catumaxomab in gastric cancer.
Lordick F; Ott K; Weitz J; Jäger D
Expert Opin Biol Ther; 2008 Sep; 8(9):1407-15. PubMed ID: 18694358
[TBL] [Abstract][Full Text] [Related]
35. First time intravesically administered trifunctional antibody catumaxomab in patients with recurrent non-muscle invasive bladder cancer indicates high tolerability and local immunological activity.
Ruf P; Bauer HW; Schoberth A; Kellermann C; Lindhofer H
Cancer Immunol Immunother; 2021 Sep; 70(9):2727-2735. PubMed ID: 33837852
[TBL] [Abstract][Full Text] [Related]
36. Immune-mediated liver injury of the cancer therapeutic antibody catumaxomab targeting EpCAM, CD3 and Fcγ receptors.
Borlak J; Länger F; Spanel R; Schöndorfer G; Dittrich C
Oncotarget; 2016 May; 7(19):28059-74. PubMed ID: 27058902
[TBL] [Abstract][Full Text] [Related]
37. Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer: an open-label, multicenter, phase I/II trial.
Ströhlein MA; Lordick F; Rüttinger D; Grützner KU; Schemanski OC; Jäger M; Lindhofer H; Hennig M; Jauch KW; Peschel C; Heiss MM
Onkologie; 2011; 34(3):101-8. PubMed ID: 21358214
[TBL] [Abstract][Full Text] [Related]
38. Influence of catumaxomab on tumor cells in bone marrow and blood in ovarian cancer.
Wimberger P; Heubner M; Lindhofer H; Jäger M; Kimmig R; Kasimir-Bauer S
Anticancer Res; 2009 May; 29(5):1787-91. PubMed ID: 19443405
[TBL] [Abstract][Full Text] [Related]
39. Inflammatory lesions of the peritoneum mimic carcinomatosis after treatment with intravenous chemotherapy and intraperitoneal catumaxomab.
Rüssel J; Stein A; Behrmann C; Hauptmann S; Krummenerl P; Schmoll HJ; Arnold D
J Clin Oncol; 2011 Aug; 29(22):e644-6. PubMed ID: 21606410
[No Abstract] [Full Text] [Related]
40. Current and future options in the treatment of malignant ascites in ovarian cancer.
Woopen H; Sehouli J
Anticancer Res; 2009 Aug; 29(8):3353-9. PubMed ID: 19661355
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
